FOI 4093 Breast Cancer Drugs

In your trust, how many patients with HER2 breast cancer are currently being treated (in the past 3 months available) with the following products;

Herceptin IV (trastuzumab IV) only Please see below table

Herceptin SC (trastuzumab SC) only Please see below table

Perjeta (pertuzumab) combined with Herceptin/Docatexel Please see below table

Kadcyla (trastuzumab emtansine) Please see below table

Tyverb (lapatinib) Please see below table

Royal Surrey County Hospital NHS Foundation Trust does not record the indication for treatment on the pharmacy dispensing system. The data may therefore include patients who have been treated with these drug for indications other than those stated in the request.

 

Drug name Total number of patients treated irrespective of indication
2017
Feb Mar Apr
LAPATINIB 250 mg Tablets 3 7 4
PERTUZUMAB 420 mg Solution for Infusion 44 47 29
TRASTUZUMAB (Herceptin) 150 mg Intravenous Infusion 25 32 12
TRASTUZUMAB (HERCEPTIN) 600 mg in 5ml Subcutaneous Injection 81 91 93
TRASTUZUMAB 399 mg in 250ml Sodium Chloride 0.9% Intravenous Infusion 8 10 6
TRASTUZUMAB 450 mg in 250ml Sodium Chloride 0.9% Intravenous Infusion 8 14 12
TRASTUZUMAB 504 mg in 250ml Sodium Chloride 0.9% Intravenous Infusion 8 8 8
TRASTUZUMAB 600 mg in 250ml Sodium Chloride 0.9% Intravenous Infusion 8 7 9
TRASTUZUMAB EMTANSINE (Kadcyla) 100 mg Powder for injection 10 12 5
TRASTUZUMAB EMTANSINE (Kadcyla) 160 mg Powder for injection 8 5 4

©2017 Royal Surrey County Hospital

Log in with your credentials

Forgot your details?